vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Graham Holdings Co (GHC). Click either name above to swap in a different company.

Graham Holdings Co is the larger business by last-quarter revenue ($1.3B vs $950.5M, roughly 1.3× Astrana Health, Inc.). Graham Holdings Co runs the higher net margin — 8.7% vs 0.7%, a 8.0% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 0.4%). Graham Holdings Co produced more free cash flow last quarter ($5.0M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 4.2%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Graham Holdings Company is a diversified American conglomerate holding company. Headquartered in Arlington County, Virginia, and incorporated in Delaware, it was formerly the owner of The Washington Post newspaper and Newsweek magazine.

ASTH vs GHC — Head-to-Head

Bigger by revenue
GHC
GHC
1.3× larger
GHC
$1.3B
$950.5M
ASTH
Growing faster (revenue YoY)
ASTH
ASTH
+42.5% gap
ASTH
42.9%
0.4%
GHC
Higher net margin
GHC
GHC
8.0% more per $
GHC
8.7%
0.7%
ASTH
More free cash flow
GHC
GHC
$11.0M more FCF
GHC
$5.0M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
4.2%
GHC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
GHC
GHC
Revenue
$950.5M
$1.3B
Net Profit
$6.6M
$108.7M
Gross Margin
Operating Margin
1.9%
3.8%
Net Margin
0.7%
8.7%
Revenue YoY
42.9%
0.4%
Net Profit YoY
184.4%
-80.2%
EPS (diluted)
$0.12
$24.76

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
GHC
GHC
Q4 25
$950.5M
$1.3B
Q3 25
$956.0M
$1.3B
Q2 25
$654.8M
$1.2B
Q1 25
$620.4M
$1.2B
Q4 24
$665.2M
$1.2B
Q3 24
$478.7M
$1.2B
Q2 24
$486.3M
$1.2B
Q1 24
$404.4M
$1.2B
Net Profit
ASTH
ASTH
GHC
GHC
Q4 25
$6.6M
$108.7M
Q3 25
$373.0K
$122.9M
Q2 25
$9.4M
$36.7M
Q1 25
$6.7M
$23.9M
Q4 24
$-7.8M
$548.8M
Q3 24
$16.1M
$72.5M
Q2 24
$19.2M
$-21.0M
Q1 24
$14.8M
$124.4M
Operating Margin
ASTH
ASTH
GHC
GHC
Q4 25
1.9%
3.8%
Q3 25
2.0%
5.2%
Q2 25
3.1%
6.0%
Q1 25
3.3%
4.1%
Q4 24
0.1%
5.8%
Q3 24
5.9%
6.8%
Q2 24
6.2%
2.2%
Q1 24
7.5%
3.1%
Net Margin
ASTH
ASTH
GHC
GHC
Q4 25
0.7%
8.7%
Q3 25
0.0%
9.6%
Q2 25
1.4%
3.0%
Q1 25
1.1%
2.0%
Q4 24
-1.2%
44.1%
Q3 24
3.4%
6.0%
Q2 24
3.9%
-1.8%
Q1 24
3.7%
10.8%
EPS (diluted)
ASTH
ASTH
GHC
GHC
Q4 25
$0.12
$24.76
Q3 25
$0.01
$27.91
Q2 25
$0.19
$8.35
Q1 25
$0.14
$5.45
Q4 24
$-0.14
$124.05
Q3 24
$0.33
$16.42
Q2 24
$0.40
$-4.79
Q1 24
$0.31
$27.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
GHC
GHC
Cash + ST InvestmentsLiquidity on hand
$429.5M
$267.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$4.8B
Total Assets
$2.2B
$8.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
GHC
GHC
Q4 25
$429.5M
$267.0M
Q3 25
$463.4M
$190.8M
Q2 25
$342.1M
$176.2M
Q1 25
$260.9M
$156.7M
Q4 24
$290.8M
$260.9M
Q3 24
$350.3M
$244.4M
Q2 24
$327.7M
$140.7M
Q1 24
$337.3M
$130.9M
Stockholders' Equity
ASTH
ASTH
GHC
GHC
Q4 25
$779.3M
$4.8B
Q3 25
$775.5M
$4.5B
Q2 25
$765.5M
$4.4B
Q1 25
$745.4M
$4.3B
Q4 24
$712.7M
$4.3B
Q3 24
$704.6M
$4.0B
Q2 24
$678.9M
$4.0B
Q1 24
$653.5M
$4.0B
Total Assets
ASTH
ASTH
GHC
GHC
Q4 25
$2.2B
$8.4B
Q3 25
$2.2B
$7.9B
Q2 25
$1.4B
$7.6B
Q1 25
$1.3B
$7.6B
Q4 24
$1.4B
$7.7B
Q3 24
$1.3B
$7.4B
Q2 24
$1.3B
$7.2B
Q1 24
$1.2B
$7.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
GHC
GHC
Operating Cash FlowLast quarter
$-2.9M
$28.3M
Free Cash FlowOCF − Capex
$-6.0M
$5.0M
FCF MarginFCF / Revenue
-0.6%
0.4%
Capex IntensityCapex / Revenue
0.3%
1.9%
Cash ConversionOCF / Net Profit
-0.44×
0.26×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$275.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
GHC
GHC
Q4 25
$-2.9M
$28.3M
Q3 25
$10.0M
$178.1M
Q2 25
$90.9M
$94.8M
Q1 25
$16.6M
$46.0M
Q4 24
$-10.9M
$116.3M
Q3 24
$34.0M
$237.6M
Q2 24
$23.2M
$52.0M
Q1 24
$6.0M
$1.1M
Free Cash Flow
ASTH
ASTH
GHC
GHC
Q4 25
$-6.0M
$5.0M
Q3 25
$7.4M
$161.8M
Q2 25
$89.5M
$78.0M
Q1 25
$13.6M
$30.5M
Q4 24
$-13.5M
$91.1M
Q3 24
$31.7M
$219.4M
Q2 24
$20.4M
$33.7M
Q1 24
$5.6M
$-20.2M
FCF Margin
ASTH
ASTH
GHC
GHC
Q4 25
-0.6%
0.4%
Q3 25
0.8%
12.6%
Q2 25
13.7%
6.4%
Q1 25
2.2%
2.6%
Q4 24
-2.0%
7.3%
Q3 24
6.6%
18.2%
Q2 24
4.2%
2.8%
Q1 24
1.4%
-1.8%
Capex Intensity
ASTH
ASTH
GHC
GHC
Q4 25
0.3%
1.9%
Q3 25
0.3%
1.3%
Q2 25
0.2%
1.4%
Q1 25
0.5%
1.3%
Q4 24
0.4%
2.0%
Q3 24
0.5%
1.5%
Q2 24
0.6%
1.5%
Q1 24
0.1%
1.8%
Cash Conversion
ASTH
ASTH
GHC
GHC
Q4 25
-0.44×
0.26×
Q3 25
26.69×
1.45×
Q2 25
9.65×
2.58×
Q1 25
2.48×
1.93×
Q4 24
0.21×
Q3 24
2.11×
3.28×
Q2 24
1.21×
Q1 24
0.40×
0.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

GHC
GHC

Products$602.7M48%
Kaplan International$251.9M20%
Manufacturing$117.8M9%
Television Broadcasting$110.5M9%
Higher Education$83.8M7%
Supplemental Education$74.9M6%
Related Party$4.4M0%

Related Comparisons